开云app官网登录入口网页版-官方正版

#分子靶向药物#

9篇内容 | 1058人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2220281, encodeId=d98a2220281f0, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a> <a href='/topic/show?id=d81511e9171a' target=_blank style='color:#2F92EE;'>#化疗相关性腹泻#</a>, objectTitle=抗肿瘤分子靶向药物致化疗相关性腹泻，全是干货！, objectType=article, longId=839166, objectId=187a83916668, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240629/1719625294625_5579292.png, objectUrl=/article/show_article.do?id=187a83916668, replyNumber=0, likeNumber=65, createdTime=2024-08-15, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=187a83916668, moduleTitle=抗肿瘤分子靶向药物致化疗相关性腹泻，全是干货！, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=187a83916668)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1677672, encodeId=e87916e7672fb, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, objectType=article, longId=211561, objectId=4f32211561f9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4f32211561f9, replyNumber=0, likeNumber=84, createdTime=2021-05-29, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4f32211561f9, moduleTitle=Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=4f32211561f9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677671, encodeId=51fd16e7671bb, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, objectType=article, longId=211270, objectId=a5bb2112e0e5, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a5bb2112e0e5, replyNumber=0, likeNumber=137, createdTime=2022-01-14, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a5bb2112e0e5, moduleTitle=肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=a5bb2112e0e5)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677669, encodeId=74da16e7669d8, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=2018 ECIL意见书：血液学和肿瘤学中免疫治疗和分子靶向药物的相关感染, objectType=article, longId=159823, objectId=f208159823cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f208159823cd, replyNumber=0, likeNumber=70, createdTime=2019-07-17, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f208159823cd, moduleTitle=2018 ECIL意见书：血液学和肿瘤学中免疫治疗和分子靶向药物的相关感染, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f208159823cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677670, encodeId=52dc16e767076, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌, objectType=article, longId=168049, objectId=57f4168049c2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=57f4168049c2, replyNumber=0, likeNumber=81, createdTime=2019-07-30, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=57f4168049c2, moduleTitle=新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=57f4168049c2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677668, encodeId=f31216e7668b9, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=一文读透：卵巢癌治疗分子靶向药物详解, objectType=article, longId=156370, objectId=19ec1563e01b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19ec1563e01b, replyNumber=0, likeNumber=94, createdTime=2019-04-28, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19ec1563e01b, moduleTitle=一文读透：卵巢癌治疗分子靶向药物详解, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=19ec1563e01b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677666, encodeId=04c916e76669c, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓, objectType=article, longId=70154, objectId=f312e015453, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f312e015453, replyNumber=0, likeNumber=88, createdTime=2016-07-18, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f312e015453, moduleTitle=ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=f312e015453)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677667, encodeId=592016e766751, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=2015非小细胞肺癌小分子靶向药物耐药处理共识发布, objectType=article, longId=77607, objectId=08cee760765, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=08cee760765, replyNumber=0, likeNumber=69, createdTime=2017-03-09, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=08cee760765, moduleTitle=2015非小细胞肺癌小分子靶向药物耐药处理共识发布, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=08cee760765)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677665, encodeId=26ad16e766508, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=快速上手指南：NSCLC 小分子靶向药物耐药处理共识, objectType=article, longId=66782, objectId=413c66e824b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=413c66e824b, replyNumber=0, likeNumber=71, createdTime=2016-09-12, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=413c66e824b, moduleTitle=快速上手指南：NSCLC 小分子靶向药物耐药处理共识, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=413c66e824b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1677664, encodeId=765116e766466, content=<a href='/topic/show?id=182231e11f0' target=_blank style='color:#2F92EE;'>#分子靶向药物#</a>, objectTitle=治疗转移性结直肠癌的分子靶向药物爱必妥®获批, objectType=article, longId=44535, objectId=301c445354e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=301c445354e, replyNumber=0, likeNumber=87, createdTime=2015-03-05, rootId=0, userName=karmond, userId=599927567154, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=301c445354e, moduleTitle=治疗转移性结直肠癌的分子靶向药物爱必妥®获批, moduleType=article, hrefUrl=//www.sandwebs.com/article/show_article.do?id=301c445354e)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 风湿免疫小助手

分子靶向药物

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#分子靶向药物# #化疗相关性腹泻#

抗肿瘤分子靶向药物致化疗相关性腹泻，全是干货！

2024-08-15发表于上海

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

Liver Cancer：仑伐替尼（Lenvatinib）治疗晚期肝细胞癌（HCC）失败后的小分子靶向药物治疗的选择

2021-05-29

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

肝细胞癌的分子靶向药物与免疫抑制剂联合治疗及其他联合治疗

2022-01-14

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

2018 ECIL意见书：血液学和肿瘤学中免疫治疗和分子靶向药物的相关感染

2019-07-17

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

新型CDK9小分子靶向药物FIT-039，有望治疗宫颈癌

2019-07-30

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

一文读透：卵巢癌治疗分子靶向药物详解

2019-04-28

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

ASCO 2016：中国自主创新小分子靶向药物埃克替尼——CONVINCE研究结果揭晓

2016-07-18

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

2015非小细胞肺癌小分子靶向药物耐药处理共识发布

2017-03-09

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

快速上手指南：NSCLC 小分子靶向药物耐药处理共识

2016-09-12

karmond (审核中...)

前往app查看评论内容

#分子靶向药物#

治疗转移性结直肠癌的分子靶向药物爱必妥®获批

2015-03-05

科室
- - 订阅+
  - 更多科室
工具
服务